Clinical trials: Eales' Disease

Eales' Disease

Lucentis (Ranibizumab) for Eales' Disease

• Completed
• Age: 21 years and older
• Phase 2/3
• Results posted

The primary objective of this protocol is to look at whether Lucentis (ranibizumab) is safe and effective when used for macular edema (retinal swelling) due to Eales' disease.

Trial name

NCT00384449

Testing

Ranibizumab

Where

United States

Volunteers

1 people

Sponsor

Oregon Health and Science University